{"nctId":"NCT01788215","briefTitle":"Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome","startDateStruct":{"date":"2010-11"},"conditions":["Polycystic Ovarian Syndrome (PCOS)","Irregular Menstrual Cycles","Androgen Excess"],"count":10,"armGroups":[{"label":"Doxycycline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: doxycycline"]},{"label":"Sugar Pill","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Sugar Pill"]}],"interventions":[{"name":"doxycycline","otherNames":[]},{"name":"Sugar Pill","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Women between 18 and 40 years of age.\n2. History of PCOS with \\< 8 periods the proceeding year\n3. Clinical or biochemical evidence of androgen excess\n4. BMI \\<40\n5. Willingness to sign consent for study including participation with collection of blood specimens\n6. Willingness to discontinue OCP for duration of study period up to 36 weeks\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Hypersensitivity to doxycycline or tetracycline\n3. History of Cushing's syndrome\n4. History of hyperprolactinemia\n5. History of congenital adrenal hyperplasia\n6. Significant hepatic impairment, including serum AST or ALT \\>1.5 times upper limits of normal.\n7. Significant renal impairment, GFR \\<60 ml/min\n8. Current use of metformin, statins, glucocorticoids, spironolactone and/or anti-estrogens.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Serum Testosterone","description":"We will determine total serum testosterone levels in all participating subjects at week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.8","spread":"13.6"},{"groupId":"OG001","value":"41.6","spread":"9.8"}]}]}]},{"type":"SECONDARY","title":"Serum Progesterone Levels in Blood","description":"Serum progesterone levels will be obtained on a weekly basis to assess ovulation. We will then perform statistical analysis on this data to determine the effectiveness of doxycycline in this study population.","paramType":null,"dispersionType":null,"classes":[]},{"type":"PRIMARY","title":"Total Serum Testosterone","description":"We will determine total serum testosterone levels in all participating subjects at week 12.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.4","spread":"10.8"},{"groupId":"OG001","value":"43.0","spread":"8.6"}]}]}]},{"type":"SECONDARY","title":"Free Testosterone in Serum","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"0.39"},{"groupId":"OG001","value":"1.16","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Free Testosterone in Serum","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"1.56"},{"groupId":"OG001","value":"1.08","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Serum Hormone Binding Globulin (SHBG)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.4","spread":"12.4"},{"groupId":"OG001","value":"39.4","spread":"10.9"}]}]}]},{"type":"SECONDARY","title":"Serum Hormone Binding Globulin (SHBG)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.8","spread":"10.6"},{"groupId":"OG001","value":"36.2","spread":"6.75"}]}]}]},{"type":"SECONDARY","title":"Total Number of Ovulations","description":"The total number of ovulations per group. Ovulation was defined as elevation of serum progesterone and or urinary pregnanediol glucuronide followed by documented menstrual bleeding within 2 weeks of elevation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":5},"commonTop":[]}}}